|
| |
Emergent BioSolutionsEmergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission—to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease.
Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. In addition to BioThrax, our biodefense product portfolio includes a next generation anthrax vaccine program, which includes a product candidate in Phase I clinical development, and a botulism program with multiple product candidates in preclinical development.
Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Our commercial product portfolio includes a typhoid vaccine candidate and a hepatitis B therapeutic vaccine candidate, both of which are in Phase II clinical development, a group B streptococcus vaccine candidate in Phase I clinical development and two vaccine candidates in preclinical development.
| Contact Details: |
| 2273 Research Boulevard, Suite 400 |
| Rockville |
| Maryland |
| 20850 |
| United States of America |
| Tel: | 301-795-1800 |
| Fax: | 301-795-1899 |
| Email: | rootk@ebsi.com |
| WWW: | www.antexbio.com/default.aspx
|
|
Loading...
|
Recent Publications by Emergent BioSolutions: |  |
Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin.
No vaccine exists for the prevention of infection with the ubiquitous... | 10th November, 2009
| Emergent BioSolutions, 300 Professional Drive, Gaithersburg, MD 20879,
| Vaccine. 2009 Nov 5.
DOI Direct Link |
Reproductive toxicity of BioThrax in rabbits.
BACKGROUND: An increasing number of women are being vaccinated during... | 1st September, 2009
| Emergent BioSolutions,
| Birth Defects Res B Dev Reprod Toxicol. 2009 Oct;86(5):370-6.
DOI Direct Link |
Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
The inclusion of an adjuvant, in addition to the existing aluminum... | 28th February, 2007
| Emergent BioSolutions, 300 Professional Drive, Gaithersburg, MD 20879,
| Vaccine. 2007 Jan 5;25(3):526-34. Epub 2006 Aug 17.
DOI Direct Link |
Press Releases on Emergent BioSolutions:
|
 |
| Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment |
26th October, 2009 |
Reportlinker |
-- A focus on "engineered" antibodies
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
|
| ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post |
30th September, 2009 |
ParagonRx |
WILMINGTON, Del., Sept. 30 /PRNewswire/ -- ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, has named Ellen M. Derrico as its chief
|
| Protein Sciences Announces Signing of a Forbearance Agreement With Emergent BioSolutions |
30th April, 2009 |
Protein Sciences Corporation |
MERIDEN, Conn., April 30 /PRNewswire/ -- Protein Sciences Corporation ("PSC"), a privately owned company based in Meriden, CT, announced today that it had signed an agreement with Emergent
|
| Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development |
18th March, 2009 |
Alliance for Biosecurity |
WASHINGTON, March 18 /PRNewswire-USNewswire/ -- David P. Wright, Co-Chair of the Alliance for Biosecurity and Chairman and CEO of PharmAthene, Inc., testified today before the House Labor, Health and
|
| VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment |
27th August, 2008 |
VaxGen, Inc. |
SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- VaxGen,
Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today provided a
financial and operational update since the
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 365 times since April 2007, the link to the organisation's website has been followed 58 times Search for more companies in Rockville Search for more companies in Maryland This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Emergent BioSolutions |
